利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.031 秒)

    Ligand for G-protein coupled receptor GPR43 and uses thereof
    4.
    发明申请
    Ligand for G-protein coupled receptor GPR43 and uses thereof 审中-公开
    G蛋白偶联受体GPR43的配体及其用途

    公开(公告)号：US20080286806A1

    公开(公告)日：2008-11-20

    申请号：US11986225

    申请日：2007-11-20

    申请人： Emmanuel LePoul ,  Michel Detheux ,  Stephane Brezillon ,  Vincent Lannoy ,  Marc Parmentier

    发明人： Emmanuel LePoul ,  Michel Detheux ,  Stephane Brezillon ,  Vincent Lannoy ,  Marc Parmentier

    IPC分类号： G01N33/53

    CPC分类号： C07K14/70567 ,  A61K31/00 ,  A61K31/19 ,  C07K14/705 ,  G01N2333/726

    摘要： The present invention is related to the G-protein coupled orphan receptor GPR43 and the identification of short chain fatty acids as natural ligands of the receptor. The invention further relates to assays for the identification of agents that modulate GPR43 ligand binding and signalling activity, as well as compositions consisting essentially of an isolated GPR43 polypeptide and an isolated short chain fatty acid. The invention also relates to diagnostic methods and kits that take advantage of the novel interaction of GPR43 with short chain fatty acids.

    摘要翻译： 本发明涉及G-蛋白偶联孤儿受体GPR 43和作为受体天然配体的短链脂肪酸的鉴定。 本发明还涉及用于鉴定调节GPR 43配体结合和信号传导活性的试剂以及基本上由分离的GPR 43多肽和分离的短链脂肪酸组成的组合物的测定。 本发明还涉及利用GPR43与短链脂肪酸的新型相互作用的诊断方法和试剂盒。

    Human pyrimidine receptor
    5.
    发明授权
    Human pyrimidine receptor 有权
    人嘧啶受体

    公开(公告)号：US07270966B2

    公开(公告)日：2007-09-18

    申请号：US10753695

    申请日：2004-01-08

    申请人： Didier Communi ,  Marc Parmentier ,  Jean-Marie Boeynaems ,  Sabine Pirotton

    发明人： Didier Communi ,  Marc Parmentier ,  Jean-Marie Boeynaems ,  Sabine Pirotton

    IPC分类号： G01N33/53 ,  C12Q1/68

    CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2217/075 ,  C12N2310/14

    摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide

    摘要翻译： 本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。 对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。 这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸 嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应

    P2Y4 Receptor transgenic and knockout non-human mammals
    6.
    发明申请
    P2Y4 Receptor transgenic and knockout non-human mammals 审中-公开
    P2Y4受体转基因和敲除非人哺乳动物

    公开(公告)号：US20070044166A1

    公开(公告)日：2007-02-22

    申请号：US11483432

    申请日：2006-07-07

    申请人： Didier Communi ,  Sabine Pirotton ,  Marc Parmentier ,  Jean-Marie Boeynaems

    发明人： Didier Communi ,  Sabine Pirotton ,  Marc Parmentier ,  Jean-Marie Boeynaems

    IPC分类号： A01K67/027

    CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2217/075 ,  C12N2310/14

    摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide

    摘要翻译： 本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。 对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。 这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸 嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应

    P2Y4 antibodies
    7.
    发明授权
    P2Y4 antibodies 有权
    P2Y4抗体

    公开(公告)号：US07312317B2

    公开(公告)日：2007-12-25

    申请号：US10811198

    申请日：2004-03-26

    申请人： Didier Communi ,  Jean-Marie Boeynaems ,  Marc Parmentier ,  Sabine Pirotton

    发明人： Didier Communi ,  Jean-Marie Boeynaems ,  Marc Parmentier ,  Sabine Pirotton

    IPC分类号： C07K16/18 ,  A61K39/395

    CPC分类号： C07K14/705 ,  A01K2217/05 ,  A01K2217/075 ,  C12N2310/14

    摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide.

    摘要翻译： 本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。 对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。 这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸 嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应。